Osteosarcoma natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
| (8 intermediate revisions by 2 users not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}}[[User:DrMars|Mohammadmain Rezazadehsaatlou[2]]]. | {{CMG}}; {{AE}}[[User:DrMars|Mohammadmain Rezazadehsaatlou[2]]]. | ||
==Overview== | ==Overview== | ||
Common complications of [[osteosarcoma]] include pathologic [[Bone fracture|fracture]] and [[metastasis]]. Pre-treatment factors that influence outcome of the osteosarcoma are primary tumor site, size of the primary tumor, and site of [[metastasis]]. After administration of preoperative [[chemotherapy]], factors that influence outcome of the [[osteosarcoma]] are adequacy of tumor resection and necrosis following induction or [[neoadjuvant chemotherapy]]. The 5 year survival rate of osteosarcoma after adequate therapy is approximately 60-80%. | Common [[complications]] of [[osteosarcoma]] include pathologic [[Bone fracture|fracture]] and [[metastasis]]. Pre-treatment factors that influence outcome of the [[osteosarcoma]] are primary [[tumor]] site, size of the primary [[tumor]], and site of [[metastasis]]. After administration of preoperative [[chemotherapy]], factors that influence outcome of the [[osteosarcoma]] are adequacy of [[tumor]] [[resection]] and [[necrosis]] following induction or [[neoadjuvant chemotherapy]]. The 5 year survival rate of [[osteosarcoma]] after adequate therapy is approximately 60-80%. | ||
== Natural History, Complications, and Prognosis == | |||
===Complications=== | |||
*The most frequent [[complications]] of [[osteosarcoma]] are pathologic [[Bone fracture|fracture]] and the development of [[metastatic]] disease.<ref name="pmid29115164">{{cite journal |vauthors=Liu W, Zhao X, Zhang YJ, Fang GW, Xue Y |title=MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma |journal=J. Int. Med. Res. |volume=46 |issue=3 |pages=975–983 |date=March 2018 |pmid=29115164 |pmc=5972241 |doi=10.1177/0300060517734114 |url=}}</ref><ref name="pmid26665241">{{cite journal |vauthors=Friebele JC, Peck J, Pan X, Abdel-Rasoul M, Mayerson JL |title=Osteosarcoma: A Meta-Analysis and Review of the Literature |journal=Am J. Orthop. |volume=44 |issue=12 |pages=547–53 |date=December 2015 |pmid=26665241 |doi= |url=}}</ref><ref name="pmid24345772">{{cite journal |vauthors=Luetke A, Meyers PA, Lewis I, Juergens H |title=Osteosarcoma treatment - where do we stand? A state of the art review |journal=Cancer Treat. Rev. |volume=40 |issue=4 |pages=523–32 |date=May 2014 |pmid=24345772 |doi=10.1016/j.ctrv.2013.11.006 |url=}}</ref><ref name="pmid27037440">{{cite journal |vauthors=Parry MC, Laitinen M, Albergo J, Jeys L, Carter S, Gaston CL, Sumathi V, Grimer RJ |title=Osteosarcoma of the pelvis |journal=Bone Joint J |volume=98-B |issue=4 |pages=555–63 |date=April 2016 |pmid=27037440 |doi=10.1302/0301-620X.98B4.36583 |url=}}</ref><ref name="pmid25022788">{{cite journal |vauthors=Yonemoto T, Hosono A, Iwata S, Kamoda H, Hagiwara Y, Fujiwara T, Kawai A, Ishii T |title=The prognosis of osteosarcoma occurring as second malignancy of childhood cancers may be favorable: experience of two cancer centers in Japan |journal=Int. J. Clin. Oncol. |volume=20 |issue=3 |pages=613–6 |date=June 2015 |pmid=25022788 |doi=10.1007/s10147-014-0729-8 |url=}}</ref><ref name="pmid27651036">{{cite journal |vauthors=Kager L, Tamamyan G, Bielack S |title=Novel insights and therapeutic interventions for pediatric osteosarcoma |journal=Future Oncol |volume=13 |issue=4 |pages=357–368 |date=February 2017 |pmid=27651036 |doi=10.2217/fon-2016-0261 |url=}}</ref> | |||
*The second most frequent [[complications]] of [[osteosarcoma]] is [[metastasis]] and meanwhile the most common sites are the regional [[lymph nodes]], other [[bone]], and [[lung]]. | |||
{| class="wikitable" | {| class="wikitable" | ||
!Complications | !Complications | ||
| Line 13: | Line 17: | ||
!Timeframe | !Timeframe | ||
|- | |- | ||
| | |[[Chemotherapy]]-related adverse effects | ||
| | |High | ||
| | |Variable | ||
|- | |- | ||
| | |[[Radiation]]-related secondary [[sarcoma]] | ||
| | |High | ||
| | |Long term | ||
|- | |- | ||
| | |Local recurrence | ||
| | |Medium | ||
| | |Variable | ||
|- | |- | ||
| | |Lung [[metastases]] | ||
| | |Medium | ||
| | |Variable | ||
|- | |- | ||
|Other bone metastases | |Other [[bone]] [[metastases]] | ||
| | |Medium | ||
| | |Variable | ||
|} | |} | ||
==Prognosis== | ===Prognosis=== | ||
The 5-year disease-free survival rates after surgical treatment with and without use of chemotherapy 15-20% and 75-80%, respectively. And the likelihood of local recurrence is 5-7% | |||
* The 5-year disease-free survival rates after surgical treatment with and without the use of [[chemotherapy]] 15-20% and 75-80%, respectively. | |||
* And the likelihood of local recurrence is 5-7% and is related to [[surgical resection]] margins and responsiveness to [[chemotherapy]]. | |||
* Pre-treatment factors that influence outcome of the [[osteosarcoma]] include the following: | |||
#Primary [[tumor]] site | |||
#Size of the primary [[tumor]] | |||
===1: Primary tumor site=== | ===1: Primary tumor site=== | ||
==== | ====Pelvis==== | ||
*Survival rates for patients with pelvic primary tumors are 20% to 47%. | *Survival rates for patients with [[Pelvis|pelvic]] primary [[tumors]] are 20% to 47%. | ||
*Complete [[surgical resection]] is associated with positive outcome for | *Complete [[surgical resection]] is associated with positive outcome for [[osteosarcoma]] of the [[pelvis]]. | ||
==== | ====Craniofacial/head and neck==== | ||
*In patients with [[craniofacial]] | *In patients with [[craniofacial]] [[osteosarcoma]], those with [[mandibular]] tumors have a significantly better [[prognosis]] than do patients with extragnathic [[Tumor|tumors]]. | ||
==== | ====Extraskeletal==== | ||
*With current combined-modality therapy, the outcome for patients with [[Extraskeletal osteosarcoma|extraskeletal]] osteosarcoma appears to be similar to that for patients with primary tumors of bone. | *With current combined-modality therapy, the outcome for patients with [[Extraskeletal osteosarcoma|extraskeletal]] [[osteosarcoma]] appears to be similar to that for patients with primary tumors of [[bone]]. | ||
===2: Size of the primary tumor=== | ===2: Size of the primary tumor=== | ||
*Larger tumors have a worse prognosis than smaller tumors. | *Larger [[Tumor|tumors]] have a worse [[prognosis]] than smaller tumors. | ||
*Tumor size has been assessed by the longest single dimension, by the cross-sectional area, or by an estimate of tumor volume. All have correlated with outcome. | *Tumor size has been assessed by the longest single dimension, by the cross-sectional area, or by an estimate of tumor volume. | ||
*Serum [[lactate dehydrogenase]] (LDH), which also correlates with outcome, is a likely surrogate for tumor volume. | *All have correlated with outcome. | ||
*[[Serum]] [[lactate dehydrogenase]] ([[Lactate dehydrogenase|LDH]]), which also correlates with the outcome, is a likely surrogate for tumor volume. | |||
===Metastatic disease=== | ===Metastatic disease=== | ||
Patients with localized disease have a much better prognosis than do patients with overt metastatic disease. As many as 20% of patients will have radiographically detectable [[Metastasis|metastases]] at diagnosis, with the [[lung]] being the most common site. The prognosis for patients with [[metastatic]] disease appears to be determined largely by the site, the number of [[metastases]], and the surgical resectability of the [[metastatic]] disease: | |||
* Patients with localized disease have a much better [[prognosis]] than do patients with overt [[metastatic]] disease. | |||
*As many as 20% of patients will have radiographically detectable [[Metastasis|metastases]] at diagnosis, with the [[lung]] being the most common site. | |||
*The [[prognosis]] for patients with [[metastatic]] disease appears to be determined largely by the site, the number of [[metastases]], and the surgical resectability of the [[metastatic]] disease: | |||
====Site of metastases==== | ====Site of metastases==== | ||
*Prognosis appears more favorable for patients with fewer [[Pulmonary nodule|pulmonary nodules]] and for those with unilateral rather than bilateral [[Pulmonary metastasis|pulmonary metastases]]. | *[[Prognosis]] appears more favorable for patients with fewer [[Pulmonary nodule|pulmonary nodules]] and for those with unilateral rather than bilateral [[Pulmonary metastasis|pulmonary metastases]]. | ||
====Number of metastases==== | ====Number of metastases==== | ||
*Patients with skip metastases (at least two discontinuous lesions in the same bone) have been reported to have poor prognosis. | *Patients with skip [[metastases]] (at least two discontinuous lesions in the same bone) have been reported to have poor [[prognosis]]. | ||
*Skip metastasis in a bone other than the primary bone should be considered systemic metastasis. | *Skip [[metastasis]] in a bone other than the primary bone should be considered systemic [[metastasis]]. | ||
*Patients with multifocal osteosarcoma (defined as multiple bone lesions without a clear primary tumor) have an extremely poor prognosis. | *Patients with multifocal [[osteosarcoma]] (defined as multiple bone lesions without a clear primary [[tumor]]) have an extremely poor [[prognosis]]. | ||
===Age=== | ===Age=== | ||
*Younger people with osteosarcoma may have a more favorable prognosis. | *Younger people with [[osteosarcoma]] may have a more favorable [[prognosis]]. | ||
* After administration of preoperative [[chemotherapy]], factors that influence outcome include the following: | |||
===Adequacy of tumor resection=== | ===Adequacy of tumor resection=== | ||
*Resectability of the tumor is a critical prognostic feature because osteosarcoma is relatively resistant to [[radiation therapy]]. | *Resectability of the [[tumor]] is a critical [[prognostic]] feature because [[osteosarcoma]] is relatively resistant to [[radiation therapy]]. | ||
*Complete resection of the primary tumor and any skip lesions with adequate margins is generally considered essential for cure. | *Complete [[resection]] of the primary tumor and any skip [[lesions]] with adequate margins is generally considered essential for cure. | ||
*A retrospective review of patients with [[craniofacial]] osteosarcoma performed by the German-Austrian-Swiss osteosarcoma cooperative group reported that incomplete surgical resection was associated with inferior survival probability. | *A retrospective review of patients with [[craniofacial]] [[osteosarcoma]] performed by the German-Austrian-Swiss [[osteosarcoma]] cooperative group reported that incomplete surgical resection was associated with inferior survival probability. | ||
===Necrosis following induction or neoadjuvant chemotherapy=== | ===Necrosis following induction or neoadjuvant chemotherapy=== | ||
*Most treatment protocols for osteosarcoma use an initial period of systemic chemotherapy before definitive resection of the primary tumor (or resection of sites of metastases). | *Most treatment protocols for [[osteosarcoma]] use an initial period of systemic chemotherapy before definitive resection of the primary tumor (or resection of sites of metastases). | ||
*The pathologist assesses necrosis in the resected tumor. | *The [[pathologist]] assesses necrosis in the resected [[tumor]]. | ||
*Patients with at least 90% [[necrosis]] in the primary tumor after induction [[chemotherapy]] have a better prognosis than those with less [[necrosis]]. | *Patients with at least 90% [[necrosis]] in the primary [[tumor]] after induction [[chemotherapy]] have a better prognosis than those with less [[necrosis]]. | ||
*Patients with less [[necrosis]] (<90%) in the primary tumor following initial [[chemotherapy]] have a higher rate of recurrence within the first 2 years compared with patients with a more favorable amount of [[necrosis]] (≥90%). | *Patients with less [[necrosis]] (<90%) in the primary [[tumor]] following initial [[chemotherapy]] have a higher rate of recurrence within the first 2 years compared with patients with a more favorable amount of [[necrosis]] (≥90%). | ||
*Less [[necrosis]] should not be interpreted to mean that chemotherapy has been ineffective; cure rates for patients with little or no necrosis following induction chemotherapy are much higher than cure rates for patients who receive no [[chemotherapy]]. | *Less [[necrosis]] should not be interpreted to mean that [[chemotherapy]] has been ineffective; cure rates for patients with little or no necrosis following induction [[chemotherapy]] are much higher than cure rates for patients who receive no [[chemotherapy]]. | ||
==References== | ==References== | ||
Latest revision as of 18:34, 19 October 2019
|
Osteosarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Osteosarcoma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Osteosarcoma natural history, complications and prognosis |
|
FDA on Osteosarcoma natural history, complications and prognosis |
|
CDC on Osteosarcoma natural history, complications and prognosis |
|
Osteosarcoma natural history, complications and prognosis in the news |
|
Blogs on Osteosarcoma natural history, complications and prognosis |
|
Risk calculators and risk factors for Osteosarcoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammadmain Rezazadehsaatlou[2].
Overview
Common complications of osteosarcoma include pathologic fracture and metastasis. Pre-treatment factors that influence outcome of the osteosarcoma are primary tumor site, size of the primary tumor, and site of metastasis. After administration of preoperative chemotherapy, factors that influence outcome of the osteosarcoma are adequacy of tumor resection and necrosis following induction or neoadjuvant chemotherapy. The 5 year survival rate of osteosarcoma after adequate therapy is approximately 60-80%.
Natural History, Complications, and Prognosis
Complications
- The most frequent complications of osteosarcoma are pathologic fracture and the development of metastatic disease.[1][2][3][4][5][6]
- The second most frequent complications of osteosarcoma is metastasis and meanwhile the most common sites are the regional lymph nodes, other bone, and lung.
| Complications | Likelihood | Timeframe |
|---|---|---|
| Chemotherapy-related adverse effects | High | Variable |
| Radiation-related secondary sarcoma | High | Long term |
| Local recurrence | Medium | Variable |
| Lung metastases | Medium | Variable |
| Other bone metastases | Medium | Variable |
Prognosis
- The 5-year disease-free survival rates after surgical treatment with and without the use of chemotherapy 15-20% and 75-80%, respectively.
- And the likelihood of local recurrence is 5-7% and is related to surgical resection margins and responsiveness to chemotherapy.
- Pre-treatment factors that influence outcome of the osteosarcoma include the following:
1: Primary tumor site
Pelvis
- Survival rates for patients with pelvic primary tumors are 20% to 47%.
- Complete surgical resection is associated with positive outcome for osteosarcoma of the pelvis.
Craniofacial/head and neck
- In patients with craniofacial osteosarcoma, those with mandibular tumors have a significantly better prognosis than do patients with extragnathic tumors.
Extraskeletal
- With current combined-modality therapy, the outcome for patients with extraskeletal osteosarcoma appears to be similar to that for patients with primary tumors of bone.
2: Size of the primary tumor
- Larger tumors have a worse prognosis than smaller tumors.
- Tumor size has been assessed by the longest single dimension, by the cross-sectional area, or by an estimate of tumor volume.
- All have correlated with outcome.
- Serum lactate dehydrogenase (LDH), which also correlates with the outcome, is a likely surrogate for tumor volume.
Metastatic disease
- Patients with localized disease have a much better prognosis than do patients with overt metastatic disease.
- As many as 20% of patients will have radiographically detectable metastases at diagnosis, with the lung being the most common site.
- The prognosis for patients with metastatic disease appears to be determined largely by the site, the number of metastases, and the surgical resectability of the metastatic disease:
Site of metastases
- Prognosis appears more favorable for patients with fewer pulmonary nodules and for those with unilateral rather than bilateral pulmonary metastases.
Number of metastases
- Patients with skip metastases (at least two discontinuous lesions in the same bone) have been reported to have poor prognosis.
- Skip metastasis in a bone other than the primary bone should be considered systemic metastasis.
- Patients with multifocal osteosarcoma (defined as multiple bone lesions without a clear primary tumor) have an extremely poor prognosis.
Age
- Younger people with osteosarcoma may have a more favorable prognosis.
- After administration of preoperative chemotherapy, factors that influence outcome include the following:
Adequacy of tumor resection
- Resectability of the tumor is a critical prognostic feature because osteosarcoma is relatively resistant to radiation therapy.
- Complete resection of the primary tumor and any skip lesions with adequate margins is generally considered essential for cure.
- A retrospective review of patients with craniofacial osteosarcoma performed by the German-Austrian-Swiss osteosarcoma cooperative group reported that incomplete surgical resection was associated with inferior survival probability.
Necrosis following induction or neoadjuvant chemotherapy
- Most treatment protocols for osteosarcoma use an initial period of systemic chemotherapy before definitive resection of the primary tumor (or resection of sites of metastases).
- The pathologist assesses necrosis in the resected tumor.
- Patients with at least 90% necrosis in the primary tumor after induction chemotherapy have a better prognosis than those with less necrosis.
- Patients with less necrosis (<90%) in the primary tumor following initial chemotherapy have a higher rate of recurrence within the first 2 years compared with patients with a more favorable amount of necrosis (≥90%).
- Less necrosis should not be interpreted to mean that chemotherapy has been ineffective; cure rates for patients with little or no necrosis following induction chemotherapy are much higher than cure rates for patients who receive no chemotherapy.
References
- ↑ Liu W, Zhao X, Zhang YJ, Fang GW, Xue Y (March 2018). "MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma". J. Int. Med. Res. 46 (3): 975–983. doi:10.1177/0300060517734114. PMC 5972241. PMID 29115164.
- ↑ Friebele JC, Peck J, Pan X, Abdel-Rasoul M, Mayerson JL (December 2015). "Osteosarcoma: A Meta-Analysis and Review of the Literature". Am J. Orthop. 44 (12): 547–53. PMID 26665241.
- ↑ Luetke A, Meyers PA, Lewis I, Juergens H (May 2014). "Osteosarcoma treatment - where do we stand? A state of the art review". Cancer Treat. Rev. 40 (4): 523–32. doi:10.1016/j.ctrv.2013.11.006. PMID 24345772.
- ↑ Parry MC, Laitinen M, Albergo J, Jeys L, Carter S, Gaston CL, Sumathi V, Grimer RJ (April 2016). "Osteosarcoma of the pelvis". Bone Joint J. 98-B (4): 555–63. doi:10.1302/0301-620X.98B4.36583. PMID 27037440.
- ↑ Yonemoto T, Hosono A, Iwata S, Kamoda H, Hagiwara Y, Fujiwara T, Kawai A, Ishii T (June 2015). "The prognosis of osteosarcoma occurring as second malignancy of childhood cancers may be favorable: experience of two cancer centers in Japan". Int. J. Clin. Oncol. 20 (3): 613–6. doi:10.1007/s10147-014-0729-8. PMID 25022788.
- ↑ Kager L, Tamamyan G, Bielack S (February 2017). "Novel insights and therapeutic interventions for pediatric osteosarcoma". Future Oncol. 13 (4): 357–368. doi:10.2217/fon-2016-0261. PMID 27651036.